CO6251371A2 - Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino - Google Patents
Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murinoInfo
- Publication number
- CO6251371A2 CO6251371A2 CO10014090A CO10014090A CO6251371A2 CO 6251371 A2 CO6251371 A2 CO 6251371A2 CO 10014090 A CO10014090 A CO 10014090A CO 10014090 A CO10014090 A CO 10014090A CO 6251371 A2 CO6251371 A2 CO 6251371A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- chain
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Anticuerpos anti-CD37 quiméricos yhumanizados y composiciones farmacéuticas que loscontienen son útiles para el tratamiento de malignidades delas células B y enfermedades autoinmunes e inflamatoriasque implican células B en su patología.1.- Una molécula de anticuerpo que se une a CD37humano y que se obtiene a partir dea) un anticuerpo monoclonal murino que está definido pori) una cadena pesada variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO: 2; yii) una cadena ligera variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO:4, o apartir deb) un anticuerpo no humano que reconoce el mismoepítopo de CD37 humano que el anticuerpo definido en a)o que reconoce un epítopo que está cerca de o sesuperpone con dicho epítopo;en el que dicha molécula de anticuerpo es un anticuerpoquimérico o humanizado.2.- Una molécula de anticuerpo de la reivindicación 1que es un anticuerpo quimérico definido pori) una cadena pesada variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO: 2;ii) una cadena ligera variable que comprende lasecuencia de aminoácidos mostrada en SEQ ID NO:4,iii) cadenas pesadas y ligeras constantes que son deorigen humano.3.- Un anticuerpo de la reivindicación 2, en el quei) la cadena pesada constante es una cadena lgG1, yii) la cadena ligera constante es una cadena kappa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07114128 | 2007-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6251371A2 true CO6251371A2 (es) | 2011-02-21 |
Family
ID=38925567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10014090A CO6251371A2 (es) | 2007-08-09 | 2010-02-09 | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino |
Country Status (37)
Country | Link |
---|---|
US (7) | US20100189722A1 (es) |
EP (3) | EP2241577A1 (es) |
JP (3) | JP5325216B2 (es) |
KR (1) | KR101593403B1 (es) |
CN (4) | CN103396490A (es) |
AR (2) | AR071242A1 (es) |
AU (1) | AU2008285590B2 (es) |
BR (2) | BRPI0815369A2 (es) |
CA (1) | CA2693464C (es) |
CL (3) | CL2008002349A1 (es) |
CO (1) | CO6251371A2 (es) |
CY (1) | CY1117101T1 (es) |
DK (1) | DK2178915T3 (es) |
EA (2) | EA027499B1 (es) |
EC (2) | ECSP109946A (es) |
ES (1) | ES2555202T3 (es) |
HK (1) | HK1220708A1 (es) |
HR (1) | HRP20160009T1 (es) |
HU (1) | HUE026221T2 (es) |
IL (1) | IL202645A (es) |
MA (1) | MA32665B1 (es) |
ME (1) | ME02300B (es) |
MY (1) | MY157555A (es) |
NZ (2) | NZ600022A (es) |
PE (3) | PE20090499A1 (es) |
PH (1) | PH12014501812A1 (es) |
PL (1) | PL2178915T3 (es) |
PT (1) | PT2178915E (es) |
RS (1) | RS54359B1 (es) |
SG (1) | SG190657A1 (es) |
SI (1) | SI2178915T1 (es) |
TN (1) | TN2010000068A1 (es) |
TW (2) | TW201512220A (es) |
UA (2) | UA103005C2 (es) |
UY (1) | UY31275A1 (es) |
WO (1) | WO2009019312A2 (es) |
ZA (1) | ZA200908758B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
US20120052061A1 (en) * | 2007-09-24 | 2012-03-01 | Tragara Pharmaceuticals Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
EP2132228B1 (en) | 2008-04-11 | 2011-06-22 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
BR112012015740B1 (pt) * | 2009-12-23 | 2020-09-29 | Synimmune Gmbh | Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico |
NO331080B1 (no) | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
MX338932B (es) | 2010-03-12 | 2016-05-06 | Immunogen Inc | Moleculas de union cd37 y sus inmunoconjugados. |
US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
US20120107317A1 (en) * | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
MX2013011385A (es) | 2011-04-01 | 2014-03-13 | Immunogen Inc | Moleculas de union a cd37 y sus inmunoconjugados. |
US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
RU2658438C2 (ru) * | 2011-12-13 | 2018-06-21 | Нордик Нановектор Аса | Химерное терапевтическое антитело нн1 против cd-37 |
BR112014024487A2 (pt) * | 2012-03-30 | 2017-08-08 | Immunogen Inc | métodos para aumentar a eficácia da terapia baseada em cd37 |
JP2015516980A (ja) * | 2012-04-26 | 2015-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd37抗体とベンダムスチンとの併用 |
US8992915B2 (en) * | 2012-05-16 | 2015-03-31 | Boehringer Ingelheim International Gmbh | Combination of CD37 antibodies with ICE |
US20130309224A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with rituximab |
WO2014151438A1 (en) * | 2013-03-15 | 2014-09-25 | Emergent Product Development Seattle, Llc | Multispecific anti-cd37 antibodies and related compositions and methods |
US20160106837A1 (en) * | 2013-06-14 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
WO2015017552A1 (en) | 2013-08-01 | 2015-02-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
US9291244B2 (en) | 2014-01-17 | 2016-03-22 | Ford Global Technologies, Llc | Nine speed automatic transmission |
EP2966085A1 (en) | 2014-07-11 | 2016-01-13 | Boehringer Ingelheim International GmbH | Antibody IgG1 with a modified heavy chain constant region |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
US20170000900A1 (en) | 2015-06-08 | 2017-01-05 | Immunogen, Inc. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
LT3124976T (lt) * | 2015-07-28 | 2018-12-27 | F. Hoffmann-La Roche Ag | Patobulintas bakterinio endotoksino testas, skirtas endotoksinų aptikimui |
MA42706A (fr) | 2015-08-28 | 2021-04-14 | Debiopharm Int Sa | Anticorps et dosages pour la détection de cd37 |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド (エイチケイ) リミテッド | 多重特異性Fab融合タンパクおよびその使用 |
US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
CN110461363B (zh) | 2017-03-16 | 2024-04-02 | 综合医院公司 | 靶向cd37的嵌合抗原受体 |
MX2019011520A (es) | 2017-03-31 | 2020-08-03 | Genmab Holding B V | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. |
WO2019006034A1 (en) * | 2017-06-27 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS |
MA52951A (fr) | 2018-06-22 | 2021-04-28 | Genmab Holding B V | Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci |
JP2021527421A (ja) * | 2018-06-22 | 2021-10-14 | ザ ジェネラル ホスピタル コーポレイション | Cd37及びcd19を標的とするキメラ抗原受容体 |
JPWO2020004337A1 (ja) * | 2018-06-27 | 2021-08-02 | 国立大学法人東海国立大学機構 | Cd37特異的キメラ抗原レセプター |
CN113365698A (zh) | 2018-10-04 | 2021-09-07 | 健玛保控股有限公司 | 包含双特异性抗cd37抗体的药物组合物 |
JP2022545834A (ja) * | 2019-08-30 | 2022-10-31 | クイル ピュージェット サウンド バイオセラピューティクス コーポレーション | 抗cd20抗体、抗cd37抗体、およびこれらの混合物 |
WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
AU2022368385A1 (en) * | 2021-10-18 | 2024-04-11 | Daiichi Sankyo Company, Limited | Anti-cd37 antibody-drug conjugate |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
CA1341351C (en) * | 1988-09-06 | 2002-03-26 | Marc D. Better | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
DE59010941D1 (de) | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2113813C (en) | 1991-08-14 | 2005-04-12 | Paula M. Jardieu | Immunoglobulin variants for specific fc epsilon receptors |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
ES2138662T3 (es) | 1993-06-03 | 2000-01-16 | Therapeutic Antibodies Inc | Produccion de fragmentos de anticuerpos. |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
WO2001049698A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
WO2003068821A2 (en) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
EP1534336A4 (en) | 2002-08-15 | 2005-12-14 | Human Genome Sciences Inc | ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
CN102940889A (zh) | 2003-05-14 | 2013-02-27 | 伊缪诺金公司 | 药物缀合物组合物 |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
EP1931709B1 (en) * | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
TWI428444B (zh) | 2005-10-12 | 2014-03-01 | Morphosys Ag | 由全長人類HuCAL GOLD-衍生之對人類CD38有特異性之治療抗體之產生及鑑定 |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
AU2008287195A1 (en) | 2007-07-06 | 2009-02-19 | Emergent Product Development Seattle, Llc | Binding peptides having a C-terminally disposed specific binding domain |
PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
EP2132228B1 (en) | 2008-04-11 | 2011-06-22 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
UA108735C2 (uk) | 2008-07-21 | 2015-06-10 | Структурні варіанти антитіл для покращення терапевтичних характеристик | |
WO2010057047A1 (en) | 2008-11-13 | 2010-05-20 | Trubion Pharmaceutics, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
JP2015516980A (ja) * | 2012-04-26 | 2015-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd37抗体とベンダムスチンとの併用 |
US20130309224A1 (en) * | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with rituximab |
US8992915B2 (en) * | 2012-05-16 | 2015-03-31 | Boehringer Ingelheim International Gmbh | Combination of CD37 antibodies with ICE |
US20160106837A1 (en) | 2013-06-14 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
-
2008
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 EP EP10168244A patent/EP2241577A1/en not_active Withdrawn
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/en active Active
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 RS RS20150817A patent/RS54359B1/en unknown
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
- 2008-08-08 CA CA2693464A patent/CA2693464C/en not_active Expired - Fee Related
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/en active Application Filing
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko active IP Right Grant
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/en active Active
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
-
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
-
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
-
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
-
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
-
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
-
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812A1/en unknown
-
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
-
2016
- 2016-01-05 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
-
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
-
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
-
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6251371A2 (es) | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino | |
PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
CA2808482C (en) | Methods for the generation of multispecific and multivalent antibodies | |
AR052889A1 (es) | Anticuerpos contra interleuquina-1 beta | |
UY29573A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
AR052065A1 (es) | Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos | |
UY30260A1 (es) | Anticuerpos dirigidos contra upar y usos de los mismos | |
PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
EA201070695A1 (ru) | Молекулы гуманизированных антител, специфичных к il-31 | |
AR062213A1 (es) | Anticuerpos dirigidos contra (alfa v beta 6) y usos de los mismos | |
PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
WO2013144566A3 (en) | Animals expressing human lambda immunoglobulin light chain variable domain | |
PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
MX2018015933A (es) | Epitopes de celulas t reguladoras, composiciones y usos para los mismos. | |
BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
CL2010000470A1 (es) | Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |